TCF4 and colorectal carcinoma: In CRC biopsy samples treated with proteasome inhibitor MG132 ex vivo, as well as in HT29 cells treated with bortezomib, we found that proteasome inhibition greatly reduced nuclear levels of pβ-Cat552 bound to TCF4 (Fig. 4C and D).